RecruitingPHASE1, PHASE2NCT04150497
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Studying Non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cellectis S.A.
- Principal Investigator
- Nitin Jain, MDM.D. Anderson Cancer Center
- Intervention
- UCART22(biological)
- Enrollment
- 52 enrolled
- Eligibility
- 15-50 years · All sexes
- Timeline
- 2019 – 2026
Study locations (19)
- University of California, Los Angeles (UCLA) - Medical Center, Los Angeles, California, United States
- University of Colorado - Aurora Cancer Center, Aurora, Colorado, United States
- Sarah Cannon - Colorado Blood Cancer Institute, Denver, Colorado, United States
- University of Chicago, Chicago, Illinois, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
- Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Weill Medical College of Cornell University, New York, New York, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Sarah Cannon - HCA Research Institute, Nashville, Tennessee, United States
- Sarah Cannon - St. David's South Austin Medical Center, Austin, Texas, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Sarah Cannon - Texas Transplant Institute at Methodist Hospital, San Antonio, Texas, United States
- University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
- CHU de Nantes - Hôtel-Dieu, Nantes, France
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04150497 on ClinicalTrials.govOther trials for Non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07222631SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomasUniversity of California, San Diego
- RECRUITINGNCT07313943PAX5-NEGATIVE HODGKIN-LIKE LYMPHOMAS: A DIAGNOSTIC CHALLANGEIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE1NCT07284927Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid MalignanciesPersonGen BioTherapeutics (Suzhou) Co., Ltd.
- RECRUITINGPHASE2NCT07283822Amping up With PemJAKSeda S. Tolu
- RECRUITINGPHASE2NCT07285590Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell LymphomaGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- RECRUITINGPHASE1NCT07283796A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's LymphomaHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT06838832Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHLChinese PLA General Hospital
- RECRUITINGNANCT06923397Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND TrialDana-Farber Cancer Institute